SCHEMBL5200014

SCHEMBL5200014

Cc1cccc(-c2n[nH]cc2-c2ccc(F)c(-c3cnn(CCN4CCOCC4)c3)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.53
NRAS P01111 1/20 0.41
FLT3 P36888 1/20 0.41
MAPK1 P28482 1/20 0.41
PIM1 P11309 2/20 0.40
PIM3 Q86V86 2/20 0.40
PIM2 Q9P1W9 2/20 0.40
FGFR1 P11362 4/20 0.40
DDR2 Q16832 1/20 0.40
FGFR2 P21802 2/20 0.40
FGFR3 P22607 2/20 0.40
KDR P35968 1/20 0.40
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39
TYK2 P29597 2/20 0.39
JAK3 P52333 2/20 0.39
ABL1 P00519 1/20 0.39
PIK3CA P42336 1/20 0.38
TYRO3 Q06418 1/20 0.38
RET P07949 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218015 0.87 TGFBR1 (0.59) TGFBR1KDR
SCHEMBL29361356 0.86 TGFBR1 (0.70) TGFBR1PIM1FGFR1DDR2PIK3CA
SCHEMBL5198271 0.86 TGFBR1 (0.70) TGFBR1PIM1FGFR1DDR2PIK3CA
SCHEMBL5199498 0.85 TGFBR1 (0.56) TGFBR1MAPK1PIM1PIM3PIM2
SCHEMBL5198295 0.85 TGFBR1 (0.56) TGFBR1JAK2JAK1TYK2JAK3
SCHEMBL5198540 0.84 TGFBR1 (0.39) TGFBR1JAK2JAK1TYK2JAK3
SCHEMBL23218007 0.84 TGFBR1 (0.54) TGFBR1
SCHEMBL5198228 0.84 TGFBR1 (0.52) TGFBR1PIM1
SCHEMBL5199757 0.84 JAK2 (0.42) TGFBR1JAK2JAK1TYK2JAK3
SCHEMBL5198955 0.82 TGFBR1 (0.47) TGFBR1NRASFLT3MAPK1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US disclosed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275968-A1 Substituted Biphenyl Derivative COL2A1, COL1A1, FGFR3 TGFBR1 40/4885NRAS 438/4885FLT3 3763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.